Immediate Impact
3 from Science/Nature 63 standout
Citing Papers
Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
Works of Shuyan Du being referenced
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
2021
BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial
2021
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Shuyan Du | 61 | 207 | 146 | 159 | 154 | 24 | 589 | |
| Adnan Ali | 132 | 134 | 63 | 256 | 165 | 35 | 589 | |
| Melissa M. Johnson | 224 | 101 | 75 | 100 | 333 | 35 | 731 | |
| H Kalbfleisch | 90 | 180 | 158 | 121 | 74 | 31 | 721 | |
| Wenbin Huang | 135 | 83 | 105 | 121 | 268 | 37 | 601 | |
| Wei Qiang Leow | 184 | 224 | 59 | 82 | 123 | 45 | 650 | |
| Yun He | 54 | 87 | 69 | 62 | 352 | 35 | 599 | |
| J.Y. Herry | 68 | 98 | 222 | 139 | 83 | 31 | 658 | |
| Jennifer Wu | 174 | 104 | 68 | 88 | 203 | 32 | 549 | |
| Vincenzo Anelli | 69 | 124 | 153 | 237 | 53 | 27 | 698 | |
| Yang‐Gun Suh | 156 | 166 | 47 | 245 | 81 | 38 | 711 |
All Works
Login with ORCID to disown or claim papers
Loading papers...